Omakase presented the POSTER “Efficiency of Third-generation antiseizure medications in Spain for Drug-resistant epilepsy: A Cost-per-Number Needed to Treat Analysis” at ISPOR 2022 and is the latest analysis we have carried out to determine the efficiency of cenobamate, a new antiseizure medication (ASM), in the treatment of refractory focal seizures in adult patients in Spain.
Our study suggests that cenobamate represents the lowest cost per NNT relative to seizure freedom, proving to represent the most efficient option compared to third generation ASMs in Spain.